Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.
about
The impact of GPCR structures on pharmacology and structure-based drug designIdentification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cellsStructural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokineAnti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices.Structural Analysis of Chemokine Receptor-Ligand Interactions.Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: molecular modeling and experimental validation.Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists.Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465.Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4Stroma targeting nuclear imaging and radiopharmaceuticals.Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonistsPharmacological modulation of chemokine receptor function.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Identifying and characterizing promiscuous targets: implications for virtual screening.Imaging agents for the chemokine receptor 4 (CXCR4).Physiology and pharmacology of plerixafor.Chemokine receptor modeling: an interdisciplinary approach to drug design.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.Metal complexes of pyridine-fused macrocyclic polyamines targeting the chemokine receptor CXCR4.MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer.Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.Evaluation of a fluorescent derivative of AMD3100 and its interaction with the CXCR4 chemokine receptor.Critical analysis of the successes and failures of homology models of G protein-coupled receptors.Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology.Aspartate-Based CXCR4 Chemokine Receptor Binding of Cross-Bridged Tetraazamacrocyclic Copper(II) and Zinc(II) Complexes.Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.CXCR4 antagonist AMD3100 elicits analgesic effect and restores the GlyRα3 expression against neuropathic pain.Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists.Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4.Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation.Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment.Structure prediction of GPCRs using piecewise homologs and application to the human CCR5 chemokine receptor: validation through agonist and antagonist docking.Insights into the mechanism of enhanced mobilization of hematopoietic progenitor cells and release of CXCL12 by a combination of AMD3100 and aminoglycoside-polyarginine conjugates.In Silico Veritas: The Pitfalls and Challenges of Predicting GPCR-Ligand Interactions
P2860
Q24628661-17F2559C-81A9-4A51-A3DB-BA624946B158Q28480517-C3F36AF3-B8B7-44CA-AD45-770E7FDEE3A8Q28910426-22EE6C9B-1145-490F-B8C4-D2853F3E852DQ31170483-A238D23E-BFC9-4717-B74E-93264E739532Q34377450-A5DD3D1F-E314-4992-A30B-8D356874CA78Q34537921-5F247DF3-3123-4BD8-893E-E40C838D0C36Q34550666-F2C88472-D12B-4C3C-ADA5-350A4D5B9143Q34752104-E071BD58-3522-415E-98CF-DCDF96FCFD87Q35036663-EF16D0BF-36FD-47C0-AD73-078A3BBB519CQ35161921-EA113B40-75CF-4CDA-A557-3B9E73C4FA62Q35887252-614AEE60-AAE7-4B69-864C-87452F62B377Q35999606-B7AAEC44-3CAD-409C-858F-66659171EA74Q37125106-FA23FEE4-FC25-404F-A5B3-EE2BED3B24BEQ37893687-E6E804D2-F8E0-492F-82FE-A94F174A9DA0Q37921284-22F33F0E-DD5B-4F76-B203-F83B9738B46EQ37999084-7FE716E4-BB3F-4358-BFCC-380F339FB411Q38022430-910F9042-D375-405A-8C72-CFFB8BCAA72CQ38157897-4361B86F-539B-407D-9083-6D929C6A5669Q38172960-A8B7C329-57F4-4950-BCA4-24F91CF1A3AAQ38196457-E0B8D46A-25AE-46D9-A42E-18CEED38EF3BQ38542935-408D49B0-A62F-45A2-B27E-5B4E76C4D698Q38838107-5E8078AD-A98B-42EB-837E-5667C2C8E5B3Q39014048-2B7814C9-902A-4962-BF8F-010C9FE6305AQ39157622-FDB24962-14D1-4F34-9C91-9FCA89FA6792Q39458347-0F2B9BD6-3B3B-480B-8356-4236E9E64CAFQ39540848-0C8826A2-0214-4FBB-9418-06F41D7911D4Q39944975-416FC976-2C50-42CE-BD63-EF921CAF4187Q40109819-D5D6DDC6-B9FF-40F7-92CB-C64FA4CE0EBCQ40599515-D4ED5DD3-038B-4E9A-AB95-1F5B6E53FD10Q40686762-F8FEF64E-CC19-48B9-8D6C-F08E9FC2CB92Q41355994-8AB3AB0C-44CE-4CCB-8D5B-72307B7E0BACQ41888022-280E3FFD-BCB4-499C-BBBD-020EB683B7B7Q42212856-350E38CD-3473-4850-8276-DF4734ECF13EQ42380472-70B2EF23-1E01-4CD7-9A3E-6547AE948462Q42803194-5368C663-CE54-4A52-9F02-CBC6507CB1E9Q42863821-FD1EADFF-EB7E-4465-B748-76B932EA4953Q44267130-551C2870-EF91-4CED-A901-1FC35EBDFAB3Q52616203-779E5588-E7EB-4656-8BC6-40B6FD06FEB7Q56992010-8BD51EB8-40E2-4299-AB21-B8835240BC98
P2860
Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Comparison of the potential mu ...... emokine receptor 4 inhibitors.
@ast
Comparison of the potential mu ...... emokine receptor 4 inhibitors.
@en
Comparison of the potential mu ...... emokine receptor 4 inhibitors.
@nl
type
label
Comparison of the potential mu ...... emokine receptor 4 inhibitors.
@ast
Comparison of the potential mu ...... emokine receptor 4 inhibitors.
@en
Comparison of the potential mu ...... emokine receptor 4 inhibitors.
@nl
prefLabel
Comparison of the potential mu ...... emokine receptor 4 inhibitors.
@ast
Comparison of the potential mu ...... emokine receptor 4 inhibitors.
@en
Comparison of the potential mu ...... emokine receptor 4 inhibitors.
@nl
P2093
P356
P1476
Comparison of the potential mu ...... emokine receptor 4 inhibitors.
@en
P2093
Gary Bridger
Jean Labrecque
Markus Metz
Rebecca S Y Wong
Simon P Fricker
Veronique Bodart
P304
P356
10.1124/MOL.108.049775
P577
2008-09-02T00:00:00Z